Roche (VTX:ROG) has been assigned a CHF 300 price target by equities researchers at Jefferies Group in a research report issued on Friday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Jefferies Group’s target price suggests a potential upside of 19.07% from the company’s current price.

Several other equities analysts also recently commented on the stock. JPMorgan Chase & Co. set a CHF 300 price objective on shares of Roche and gave the company a “buy” rating in a research note on Thursday. Barclays set a CHF 305 price objective on shares of Roche and gave the company a “buy” rating in a research note on Tuesday. Nord/LB reissued a “buy” rating on shares of Roche in a research note on Tuesday. Goldman Sachs Group set a CHF 325 price objective on shares of Roche and gave the company a “buy” rating in a research note on Wednesday, December 13th. Finally, Deutsche Bank set a CHF 264 price objective on shares of Roche and gave the company a “neutral” rating in a research note on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. Roche presently has an average rating of “Hold” and an average target price of CHF 263.42.

Shares of Roche (VTX:ROG) opened at CHF 251.95 on Friday. Roche has a twelve month low of CHF 226.10 and a twelve month high of CHF 273. The firm has a market cap of $217,190.00 and a P/E ratio of 22.40.

ILLEGAL ACTIVITY NOTICE: “Roche (ROG) PT Set at CHF 300 by Jefferies Group” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/05/roche-rog-pt-set-at-chf-300-by-jefferies-group.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.